Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

When Switching Patients to Biosimilars, Communication & Expert Nurses Reduce the Nocebo Effect

  |  

In interviews, patients indicated the nurses’ experiences with switching medications were valuable, a finding that has not previously been published in the literature. Based on these interviews, the authors concluded the nurses played an important role in the intervention, particularly as the first point of contact for announcing the medication switch to patients. The authors suggest that, although intervention content may differ by countries and biosimilar treatments, the methodology they used to construct the intervention may be generally useful to improve the outcomes of medication changes.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Petit J, Antignac M, Poilverd RM, et al. Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar. RMD Open. 2021 Jan;7(1):e001396.

Related Articles

    Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

    SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Biosimilars Great Debate: To Switch or Not?

    SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

    Medicalwriters/Science Source

    Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

    As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…